Statins alter gut microbial communities by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, potentially explaining the lower T2DM incidence in obese users (5.9% vs. 17.7%) (Zhou H. et al., 2023; Vieira-Silva et al., 2020). This evidence concerns the gene HMGCR and type 2 diabetes mellitus.